Diabetes Drug Aids Alcohol Use Disorder

Oral semaglutide, a medication primarily known for treating diabetes and aiding weight loss, is showing potential as a new treatment for alcohol use disorder (AUD). Recent research indicates that this drug can significantly reduce heavy drinking in adults struggling with AUD.

A study published in The American Journal of Psychiatry evaluated the oral form of semaglutide, finding it decreased heavy drinking days, reduced overall alcohol consumption, and lowered cravings. Importantly, these benefits were observed even in individuals who did not experience weight loss, suggesting the drug's impact on drinking is separate from its effects on appetite or weight.

This development is significant given the limited number of approved medications for AUD, a chronic condition affecting millions. The research, involving 50 participants over eight weeks, showed a consistent reduction in harmful drinking behaviors and alcohol-related problems. Experts caution that further, larger studies are required before semaglutide can be officially recommended for AUD treatment, but the initial results are highly encouraging.

Researchers also noted a potential mechanism involving reduced dopamine signaling in brain reward areas. The medication was generally well-tolerated, with mild side effects and high adherence rates, indicating its feasibility for clinical use. This offers a potential new option for those unresponsive to existing treatments and could lessen alcohol-related harms.